Cable company grid publicity "typical violations"
Release time:
2022-12-22
近期，为了能让全体员工顺利、熟练地掌握新“工贸企业50条典型违章行为”条款，电缆公司采用网格化管理模式，以各中层骨干每人带多人的方式分成12个组来开展关于“典型违章行为”的安全管理工作。
和上半年的典型违章行为50条内容相比，下半年新出的关于一般工贸企业员工典型违章行为50条的内容有了明显的改动。比如以前是11大块内容，而现在细化到9大块内容，有些大块的内容比之前有所增加，也有内容比以前有所减少。此外，原先的作业票、操作作业、设备检修作业和现场恢复这四大块内容，现在合并统称作业安全这一大块内容；“着装与劳动防护”改成了“劳动纪律”；“其他”变成了“通行安全”；还增加了“装卸作业”这一大块内容。总之，在内容方面，更改后的违章内容更加贴近企业自身安全情况，有利于员工根据工作中的实际情况，以便更好地熟知和掌握。网格化管理模式的开展，把组长和相关组员捆绑在一起，组长会时刻关注组员的掌握情况，并会抽时间到现场进行指导，特别是对于那些年纪大、掌握相对困难的员工，组长都会耐心指导。各组长还会和之前的典型违章行为版本做对比，着重和组员讲解变更后的典型违章内容，让他们加深印象，也努力让他们去理解和掌握其中的意思。另外，安环部在总经理助理汪德波的带领下，也会不定期去岗位上和部门里进行实地抽查，现场提问50条相关内容，测评员工的掌握情况。
值得一提的是，为了有效提高员工熟练掌握50条违章行为内容的积极性和主动性，公司还制定了一些奖励机制。比如12月安全奖100元/月不变，被集团公司安委会抽到书面或口头测试的人员及网格组长，安全奖基数调整为200元；参与书面考试或口头测试的人员，评分80分以上（含）为合格（100分制），则安全奖按200*0.8=160元计算，以此类推；参与书面考试或口头测试的人员，评分80分以下，则取消当月安全奖；各网格组长和各组员的安全奖金挂钩，与被抽测人员的安全奖金同时上下浮动。
电缆公司运用网格化管理模式开展熟背“典型违章行为”工作，有助于提升各中层骨干对员工的管理效率、管理能力和管理水平，加快活动落实速度，整合管理资源，促进精细化管理，最终形成一套有效的监督管理机制。（黄媛）
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page